Table 3. Details of Bevacizumab Treatment and Response.

Patient No	Site of target lesion(s)	Largest target lesion (cm)	Concurrent chemotherapy regimen	Dosage of bevacizumab	No. cycles of bevacizumab	Response
1	Liver	6.1	None	7 mg/kg IV every 2 weeks	3	Progression
2	Abdomen	18	Carboplatin/paclitaxel; liposomal doxorubicin	5 mg/kg IV every 3 weeks	10	Stable
3	Liver	4.2	Gemcitabine, then leuprolide acetate; docetaxel	7.5 mg/kg IV every 2 weeks	12	PR
4	NMD	N/A	Etoposide	7 mg/kg IV every 2 weeks	6	Progression
5	Colon	3.2	Carboplatin/paclitaxel; paclitaxel	7 mg/kg IV every 4 weeks	12	PR
6	Cul-de-sac	7.4	None	10 mg/kg IV every 2 weeks	6	CR
7	Liver	5	Paclitaxel	5 mg/kg IV every 2 weeks	2	Stable
8	Liver	12.5	None	15 mg/kg IV every 3 weeks	3	Progression

NMD: no measurable disease; IV: intravenously; PR: partial response; CR: complete response